CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 1,387 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 1,387 shares of the firm’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $18.00, for a total value of $24,966.00. Following the transaction, the chief financial officer directly owned 147,683 shares of the company’s stock, valued at $2,658,294. The trade was a 0.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Price Performance

Shares of NASDAQ:CBLL opened at $18.80 on Wednesday. The company has a market cap of $713.27 million, a P/E ratio of -11.53 and a beta of 0.99. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $24.33. The business has a fifty day simple moving average of $19.09 and a 200-day simple moving average of $19.24.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The firm had revenue of $26.49 million for the quarter, compared to analysts’ expectations of $26.09 million. Equities research analysts forecast that CeriBell, Inc. will post -1.69 EPS for the current year.

Wall Street Analyst Weigh In

CBLL has been the topic of a number of recent research reports. Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. BTIG Research restated a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. Finally, Canaccord Genuity Group reduced their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.20.

Hedge Funds Weigh In On CeriBell

Several institutional investors have recently made changes to their positions in CBLL. Bank of New York Mellon Corp grew its holdings in shares of CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after purchasing an additional 1,162,200 shares during the last quarter. KCM Capital Inc bought a new position in shares of CeriBell during the fourth quarter valued at approximately $21,930,000. Royce & Associates LP bought a new position in shares of CeriBell during the fourth quarter valued at approximately $11,695,000. Adage Capital Partners GP L.L.C. bought a new position in shares of CeriBell during the fourth quarter valued at approximately $10,965,000. Finally, CenterBook Partners LP grew its holdings in shares of CeriBell by 448.0% during the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after purchasing an additional 389,584 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.